
Health:
In clinical studies over the past 20 years, our licensed Immunitor oral pill immunotherapeutics have consistently proven the science and demonstrated superior safety and efficacy in diseases such as late-stage cancers, tuberculosis, HIV/AIDS, hepatitis.In many cases where other treatments have failed.
Key Capital is now working with Immunitor towards product registrations and commercializations that will contribute to a better healthcare future.
Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine
NEW YORK, NY, January 6, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that it is fast becoming clear that the approach to global COVID-19 vaccination is in crisis.
Key Capital Invites Partnering Inquiries for COVID-19 Therapeutic Vaccine.